Economic Burden of Elderly Patients With Acute Myeloid Leukemia Treated in Routine Clinical Care in the United States

Acute myeloid leukemia (AML) is a heterogeneous hematologic neoplasm characterized by clonal proliferation of myeloid precursor cells in the peripheral blood, bone marrow, and/or other tissues [1]. There are an estimated 21,000 new cases of AML diagnosed annually in the United States (US), with the incidence steadily increasing at about 5% per year [2,3]. AML is generally a disease affecting elderly patients, with a median age at diagnosis of 69 years [4]. The overall prognosis for AML is poor, with less than 30% of patients surviving 5 years from diagnosis; however, outcomes vary according to multiple prognostic factors, including cytogenetics, molecular abnormalities, age, and performance status [3].

Source: Leukemia Research - June 16, 2018 Category: Hematology Authors: Jill A. Bell, Aaron Galaznik, Eileen Farrelly, Marlo Blazer, Sharanya Murty, Augustina Ogbonnaya, Mike Eaddy, Robert J. Fram, Douglas V. Faller, Vamsi Kota Tags: Research paper Source Type: research